Important Shipping Update. We’ve got you covered! Due to new U.S. import regulations, orders may take a bit longer to arrive as they go through additional customs checks — but don’t worry! All extra import fees and tariffs are fully covered by us — you pay nothing extra. Shop confidently — your savings stay safe! Important Shipping Update. We’ve got you covered! Due to new U.S. import regulations, orders may take a bit longer to arrive as they go through additional customs checks — but don’t worry! All extra import fees and tariffs are fully covered by us — you pay nothing extra. Shop confidently — your savings stay safe! Important Shipping Update. We’ve got you covered! Due to new U.S. import regulations, orders may take a bit longer to arrive as they go through additional customs checks — but don’t worry! All extra import fees and tariffs are fully covered by us — you pay nothing extra. Shop confidently — your savings stay safe!
Our
blog image
articles
Our-articles
Published: December 29, 2023

Durolane Hip Injection: Does Hyaluronic Acid Treatment Bring Comfort?

A Durolane hip injection is a single 3 mL dose (60 mg) of stabilized, non-animal hyaluronic acid placed into the hip joint under ultrasound or fluoroscopic guidance to ease osteoarthritis pain. Whether it brings comfort depends on where you are and what evidence you weigh: in the United States the FDA approved Durolane only for knee osteoarthritis, so a hyaluronic acid hip injection with Durolane is off-label there, while Canadian and European labeling include the hip.

The clinical evidence is mixed. Open studies report that many patients feel better after a single injection, but the one randomized trial that tested Durolane in the hip against saline found no meaningful benefit, and both the AAOS and the ACR advise against hyaluronic acid for hip osteoarthritis. A Durolane injection in the hip is therefore a judgment call for a specialist, not a routine first step.

This guide is written for licensed practitioners and clinic buyers, with plain-language notes for patients. For the product basics (composition, dosing, how NASHA gel works), see our overview what Durolane is and how it is used.

Key Takeaways

  • US status: Durolane (PMA P170007, approved August 29, 2017) is indicated only for knee osteoarthritis pain; its FDA labeling states that other joints have not been studied, so hip use in the US is off-label.
  • Canada and EU: labeling covers mild to moderate knee or hip osteoarthritis, with the same 3 mL dose for the hip as for the knee.
  • Evidence: in a 77-patient randomized trial, 11% of hips responded to Durolane versus 21% to saline and 74% to a corticosteroid; network meta-analyses of 1,353 and 1,254 patients found no injection clearly better than saline or standard care.
  • Guidelines: the AAOS (2023) strongly recommends against hyaluronic acid for hip osteoarthritis, and the ACR (2019) strongly recommends against it.
  • Technique: the hip is deep, so the Canadian labeling requires fluoroscopic or ultrasound guidance to confirm the needle is inside the joint.

durolane hip injection

Is Durolane Approved for the Hip? US, Canada and EU Labeling

Durolane’s regulatory status for hip arthritis is not the same everywhere, and this is the single most important point for any clinic that stocks it.

United States. Durolane is a Class III device approved through the FDA premarket approval P170007 in August 2017. Its indication is pain in osteoarthritis of the knee in patients who have not responded adequately to conservative non-drug therapy or simple analgesics such as acetaminophen. The labeling is explicit about other joints:

“The safety and effectiveness of DUROLANE® in joints other than the knee have not been studied.” FDA, Durolane Instructions for Use (PMA P170007)

A US physician may still choose to use Durolane in the hip as off-label practice, but the patient should be told so, and payers generally do not cover it: Medicare local coverage policies such as Palmetto GBA’s LCD L39260 are written for hyaluronic acid injections in knee osteoarthritis only.

Canada. The Canadian labeling published by Bioventus includes the hip:

“DUROLANE is indicated for the symptomatic treatment of mild to moderate knee or hip osteoarthritis.” Bioventus, DUROLANE Canada, Summary of Indications for Use

The Canadian instructions for use add the ankle, fingers and toes, and pain after arthroscopy in an osteoarthritic joint within 3 months of the procedure. The recommended dose is the full 3 mL syringe for a knee or hip joint.

European Union and other markets. According to the manufacturer’s international summary of indications, the EU labeling also covers mild to moderate knee or hip osteoarthritis, and in the EU, Australia and New Zealand it extends to the ankle, shoulder, elbow, wrist, fingers and toes. That is why patients in the Netherlands and Belgium searching for “Durolane infiltraties” in the hip are reading about an on-label use in their country. Mexico and Taiwan, by contrast, list the knee only.

How a Durolane Hip Injection Works

Durolane is made with NASHA technology: hyaluronic acid produced by bacterial fermentation and lightly stabilized into a gel at 20 mg/mL. It is not synthetic, not animal-derived and not a steroid. The stabilization is intended to keep the gel in the joint longer than an unmodified sodium hyaluronate solution, which is why one injection replaces the three to five weekly shots that older products require.

In an osteoarthritic hip, the synovial fluid loses viscosity and elasticity. The rationale for viscosupplementation is to restore some of that cushioning and lubrication and to dampen pain signaling for several months. That rationale is better supported in the knee than in the hip. Earlier versions of this page claimed that Durolane can slow the progression of hip osteoarthritis; no randomized trial has shown that, and the FDA labeling makes no such claim.

The practical appeal is one visit, one injection and no steroid exposure. Licensed buyers can order Durolane 60 mg/3 mL or view the full Durolane brand page through a verified OGOmed account.

What the Evidence Shows for Hyaluronic Acid Hip Injections

Searches for “Durolane hip injection reviews” and “Durolane injection success rate” usually lead to open, uncontrolled reports. Those results look encouraging, but in hip osteoarthritis a saline injection alone often produces a clinically noticeable improvement, so controlled trials matter most.

Study Design and patients Main result
Berg and Olsson, 2004 Open pilot, 31 hips, single NASHA injection Response rate 50% at 2 weeks and 54% at 3 months; no control group
Conrozier et al., 2009 Open follow-up in daily practice, 40 patients, fluoroscopy-guided 71% met OMERACT-OARSI responder criteria; 15 of 28 had a transient pain increase in the first week
Atchia et al., 2011 Randomized, 77 patients: Durolane vs saline vs methylprednisolone vs no injection, ultrasound-guided Responders: steroid 74%, saline 21%, Durolane 11%, no injection 10%
Long and Fitzpatrick, 2021 Case series, 87 patients with mild to moderate hip OA, ultrasound-guided Durolane Modified Harris Hip Score rose from 58.5 to 71.3 at 6 weeks; no control group
Gazendam et al., 2021 Network meta-analysis, 11 RCTs, 1,353 patients No injection (steroid, HA, PRP) outperformed saline for pain or function up to 6 months
Liu et al., 2026 Network meta-analysis, 14 studies, 1,254 patients No injection type differed significantly from standard care or placebo at 3, 6 or 12 months

The open studies came first. A Swedish pilot published in Clinical and Experimental Rheumatology (2004) and a French practice-based series in Archives of Orthopaedic and Trauma Surgery (2009) both reported responder rates above 50%, and both authors called for controlled trials. A more recent Australian case series of 87 patients, published in BMC Musculoskeletal Disorders (2021), found an improvement that exceeded the minimal clinically important difference at 6 weeks; one author disclosed prior membership of a Bioventus advisory board.

The only randomized trial of Durolane in the hip tells a different story. In the study by Atchia and colleagues, published in Annals of the Rheumatic Diseases (2011), patients with moderate to severe hip osteoarthritis received a single ultrasound-guided injection. Only the corticosteroid group improved significantly; Durolane performed no better than saline or no injection. The trial was small, and it enrolled more advanced disease than the labeling targets, so it does not settle the question for mild to moderate hips.

Pooled analyses lean the same way. A 2018 meta-analysis of eight randomized trials (807 patients) in Archives of Physical Medicine and Rehabilitation found no evidence that hyaluronic acid beats placebo for hip pain at 3 months, and its authors did not recommend viscosupplementation for the hip. The network meta-analysis in the British Journal of Sports Medicine (2021) concluded that intra-articular saline performed as well as every active injection, and a 2026 update in the Orthopaedic Journal of Sports Medicine found no significant differences out to 12 months. In short, many patients do feel better after a hyaluronic acid hip injection, but controlled data do not show that the hyaluronic acid itself is responsible.

What Guidelines Say About Hyaluronic Acid for Hip Osteoarthritis

US professional guidelines are firmer about the hip than about the knee. The American Academy of Orthopaedic Surgeons published its updated hip osteoarthritis guideline in December 2023 (announced in January 2024, replacing the 2017 edition). It includes a strong recommendation that:

“intraarticular hyaluronic acid should not be considered for treatment of symptomatic OA of the hip” AAOS, Management of Osteoarthritis of the Hip Guideline Update, 2023

The AAOS gives the reason in the same recommendation: hyaluronic acid does not improve function or reduce pain better than placebo. The same update makes a moderate recommendation that intra-articular corticosteroids could be considered for short-term relief. The 2017 edition of the AAOS hip guideline had reached the same conclusion on hyaluronic acid.

The 2019 American College of Rheumatology/Arthritis Foundation guideline conditionally recommends against hyaluronic acid in the knee but strongly recommends against it in hip osteoarthritis. In ACR terms, a strong recommendation means the panel was confident the advice applies to all or almost all patients.

European experts are more favorable. The EUROVISCO group, a Delphi panel of rheumatologists and orthopedic surgeons whose 2026 hip recommendations appeared in Cartilage, supports viscosupplementation for hip osteoarthritis in patients who do not need surgery, mainly in mild to moderate disease, always under imaging guidance. This is expert consensus built partly on observational data, not a trial result.

The Durolane Hip Injection Procedure: Why Image Guidance Matters

The hip joint sits deep beneath muscle, close to the femoral artery, vein and nerve. Landmark-guided (“blind”) injections are less reliable here than in the knee, and the gel must reach the joint cavity to have any chance of working. The Canadian Durolane instructions for use therefore state that the hip injection should be given under fluoroscopic control, preferably with contrast medium, or under ultrasound control to confirm needle position.

A typical image-guided procedure in a specialist setting looks like this:

  • Assessment: history, examination and a recent X-ray to confirm hip osteoarthritis and grade its severity; ultrasound may also show effusion or synovitis.
  • Preparation: the patient lies supine, the skin is disinfected, and local anesthetic is usually given along the needle path.
  • Needle placement: the physician advances an 18 to 22 G needle of adequate length (the labeled range) into the anterior hip capsule under live ultrasound or fluoroscopy. Any joint effusion is aspirated first.
  • Injection: the full 3 mL syringe is injected slowly. With fluoroscopy, a small amount of contrast confirms intra-articular spread; patients allergic to contrast need ultrasound instead.
  • Aftercare: the FDA labeling advises avoiding strenuous activity and prolonged weight-bearing (more than about an hour) for 48 hours. Normal walking is not restricted.

The injection itself usually takes a few minutes; most of the appointment is preparation and imaging.

Durolane Hip Injection Side Effects and Safety

Side effects in the hip are similar in type to those in the knee: local and usually short-lived. The Canadian labeling notes that most adverse reactions in knee and hip studies were transient pain, swelling or stiffness in the joint, of mild or moderate intensity. In the hip series, the pattern was consistent:

  • Post-injection pain flare: 15 of 28 assessable patients in the Conrozier series had a temporary increase in hip pain during the first week, and 9 of 31 in the Berg pilot reported a short-lived worsening of pain or stiffness.
  • Injection-site pain: 5 of 87 patients in the Long series; no serious adverse events were recorded.
  • Procedure risks: any joint injection carries a small risk of infection; deep hip injections add the risks of imaging, such as contrast allergy.
  • Labeled cautions: do not inject into an infected joint or through infected or diseased skin; do not use in patients with known hypersensitivity to hyaluronic acid preparations; use caution in pre-existing chondrocalcinosis, where injection may trigger an acute attack.

Durolane is not a steroid, and it is not made from poultry, so egg or feather allergy is not a concern. Safety in pregnancy, breastfeeding and patients aged 21 or younger has not been established. A new hot, swollen joint after any injection should be assessed for infection before it is attributed to the product. For more detail, see our article on potential side effects of Durolane.

Who Might Be a Candidate for a Hyaluronic Acid Hip Injection

Given the guideline position, a Durolane injection in the hip is best viewed as a selective option after shared decision-making, not a default. Patients most often considered are those with:

  • Radiographically confirmed mild to moderate hip osteoarthritis (the population named in the Canadian and EU labeling), whose pain persists despite exercise, weight management and analgesics.
  • Reasons to avoid or limit corticosteroid injections, such as poorly controlled diabetes or a poor or short-lived response to previous steroid shots.
  • A wish to postpone surgery, accepting that the benefit may be modest and uncertain.

Patients with severe hip OA (bone-on-bone narrowing, femoral head collapse or marked deformity) are poor candidates; the most recent Durolane hip series excluded them, and the randomized trial that enrolled moderate to severe hips found no effect. Patients already scheduled for hip replacement should also wait: the EUROVISCO panel advises against arthroplasty within 3 months of a hip viscosupplement injection. In the US, every candidate should be told that hip use is off-label and that insurance is unlikely to pay for the product.

Alternatives to Durolane for Hip Arthritis

For most patients, a hyaluronic acid hip injection is not the first treatment to try. The AAOS 2023 guideline gives its strongest support to oral NSAIDs (when not contraindicated) and moderate support to physical therapy for mild to moderate disease. Other options include:

  • Exercise and weight loss: strongly recommended for hip osteoarthritis by the ACR.
  • Intra-articular corticosteroid: the injection with the best short-term data in the hip, including the 74% responder rate in the Atchia trial, though the effect fades over weeks to months.
  • Platelet-rich plasma: studied in several trials, but the network meta-analyses above found it no better than saline.
  • Other viscosupplements: single-injection Synvisc-One and Monovisc and three-injection Euflexxa are FDA-approved for the knee only, so they share Durolane’s off-label status in a US hip. Our Durolane vs Synvisc comparison covers the differences between products.
  • Total hip arthroplasty: the definitive treatment for advanced osteoarthritis with persistent pain and loss of function.
WHOLESALE ACCOUNT

Wholesale access for aesthetic professionals

3,000+
Aesthetic practitioners buying wholesale
Exclusive
Personal discounts for registered customers
10,000+ Orders Delivered Fast, reliable, and trackable shipping
Delivery Guaranteed Lost or damaged? We’ll replace your order for free
Secure Payment Encrypted checkout protection
Trusted Supplier Verified quality & support
Register for free →

Is a Durolane Hip Injection Worth It?

A Durolane hip injection is a reasonable option for a narrow group: patients with mild to moderate hip osteoarthritis who have tried first-line care, prefer to avoid repeated steroids, and accept that controlled trials have not shown a clear advantage over saline. Where it is labeled for the hip, as in Canada and the EU, it is an approved single-visit treatment; in the United States it remains off-label, outside AAOS and ACR recommendations and usually outside insurance coverage.

If it is used, it should be given under ultrasound or fluoroscopic guidance by a trained specialist, as part of a broader plan that includes exercise, weight management and analgesics, with realistic expectations about how long any relief may last. Viscosupplements are prescription devices and should be purchased and administered only by licensed healthcare professionals.

Last updated: November 2026.

Frequently Asked Questions
Is Durolane approved for hip injections?

It depends on the country. In the United States, the FDA approved Durolane only for knee osteoarthritis pain, and its labeling states that other joints have not been studied, so hip use is off-label. In Canada and the European Union, the labeling covers symptomatic treatment of mild to moderate knee or hip osteoarthritis, using the same 3 mL dose in the hip.

How long does a Durolane hip injection take to work?

Response, if it comes, is usually seen within a few weeks. In an open pilot study of 31 hips, 50% of patients met the response criteria at 2 weeks and 54% at 3 months. Some patients first notice a temporary increase in hip pain during the first week, which settles. Controlled trials have not confirmed that the improvement exceeds what saline produces.

What is the success rate of Durolane hip injections?

Reported success rates vary widely with study design. Open studies without a control group report responder rates of about 50% to 71%. In the only randomized trial of Durolane in the hip, 77 patients with moderate to severe osteoarthritis, just 11% responded to Durolane, compared with 21% to saline and 74% to a corticosteroid injection.

Is Durolane a steroid?

No. Durolane is stabilized sodium hyaluronate, a gel form of a substance naturally present in joint fluid, produced by bacterial fermentation. It is regulated as a medical device, not a drug, and contains no corticosteroid. In hip trials it has been compared with the steroid methylprednisolone, which gave faster and stronger short-term relief.

Can Durolane be injected into the shoulder?

Only where the local labeling allows it. Durolane’s labeling in the EU, Australia and New Zealand includes osteoarthritis pain in the shoulder, elbow, wrist, ankle, fingers and toes. The Canadian labeling covers the knee, hip, ankle, fingers and toes, and the US labeling covers the knee only, so a shoulder injection in the US is off-label.